Loss of AMPKα 1 expression is associated with poor survival in melanoma patients

Journal of Investigative Dermatology

Volumn 134, Issue 6, 2014, Pages 1763-1766

  Bhandaru, Madhuri ^a   Martinka, Magdalena ^a   Li, Gang ^a   Rotte, Anand ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMP ACTIVATED PROTEIN KINASE ALPHA 1; B RAF KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; MICROPTHALMIA INDUCED TRANSCRIPTION FACTOR; PROTEIN 14 3 3; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA1;

CANCER INHIBITION; CANCER PROGNOSIS; CHROMOSOME ABERRATION; DESMOPLASTIC MELANOMA; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; DYSPLASTIC NEVUS; ENZYME ACTIVATION; GENE AMPLIFICATION; HUMAN; LETTER; MELANOMA; METASTASIS INHIBITION; METASTATIC MELANOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; TISSUE MICROARRAY; ULCER; UPREGULATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; HUMAN TISSUE; OVERALL SURVIVAL; PRIORITY JOURNAL;

AMP-ACTIVATED PROTEIN KINASES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84900843054     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.26     Document Type: Letter

References (15)

1. Borgdorff V, Rix U, Winter GE et al. (2013) A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF. Oncogene doi:10.1038/onc.2013.185
2. Cerezo M, Tichet M, Abbe P et al. (2013) Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol Cancer Ther 12:1605-15
3. Finn L, Markovic SN, Joseph RW (2012) Therapy for metastatic melanoma: the past, present, and future. BMC Med 10:23
4. Kim I, He YY (2013) Targeting the AMP-activated protein kinase for cancer prevention and therapy. Front Oncol 3:175
5. Lee YK, Park SY, Kim YM et al. (2010) Suppression of mTOR via Akt-dependent and-independent mechanisms in selenium-treated colon cancer cells: involvement of AMPKalpha1. Carcinogenesis 31:1092-9
6. Liang J, Mills GB (2013) AMPK: a contextual oncogene or tumor suppressor? Cancer Res 73:2929-35
7. Martin MJ, Hayward R, Viros A et al. (2012) Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov 2:344-55
8. Miller AJ, Mihm MC Jr (2006) Melanoma. N Engl J Med 355:51-65
9. Pryor JG, Brown-Kipphut BA, Iqbal A et al. (2011) Microarray comparative genomic hybridization detection of copy number changes in desmoplastic melanoma and malignant peripheral nerve sheath tumor. Am J Dermatopathol 33:780-5
10. Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138-40
11. Shen CH, Yuan P, Perez-Lorenzo R et al. (2013) Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. Mol Cell 52:161-72
12. William WN, Kim JS, Liu DD et al. (2012) The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol 23:78-85
13. Yuan P, Ito K, Perez-Lorenzo R et al. (2013) Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma. Proc Natl Acad Sci USA 110:18226-31
14. Zheng B, Jeong JH, Asara JM et al. (2009) Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 33:237-47
15. Zheng L, Yang W, Wu F et al. (2013) Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clin Cancer Res 19:5372-80